• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
D-Pharm Ltd. - Product Pipeline Review - Q4 2010 - Product Image

D-Pharm Ltd. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 46 pages
  • Global Markets Direct

D-Pharm Ltd. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “D-Pharm Ltd. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- D-Pharm Ltd. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of D-Pharm Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- READ MORE >



List of Tables
List of Figures
D-Pharm Ltd. Snapshot
D-Pharm Ltd. Overview
Key Information
Key Facts
D-Pharm Ltd. – Research and Development Overview
Key Therapeutic Areas
D-Pharm Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
D-Pharm Ltd. – Pipeline Products Glance
D-Pharm Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
D-Pharm Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
D-Pharm Ltd.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
D-Pharm Ltd. – Drug Profiles
DP-b99
Product Description
Mechanism of Action
R&D Progress
DP-VPA
Product Description
Mechanism of Action
R&D Progress
DP-b99
Product Description
Mechanism of Action
R&D Progress
DP-388
Product Description
Mechanism of Action
R&D Progress
DP-460
Product Description
Mechanism of Action
R&D Progress
DP-71
Product Description
Mechanism of Action
R&D Progress
D-Pharm Ltd. – Pipeline Analysis
D-Pharm Ltd. – Pipeline Products by Therapeutic Class
D-Pharm Ltd. Pipeline Products By Target
D-Pharm Ltd. – Pipeline Products by Route of Administration
D-Pharm Ltd. – Pipeline Products by Molecule Type
D-Pharm Ltd. – Recent Pipeline Updates
D-Pharm Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 03, 2010: D-Pharm Appoints CRO For Clinical Development Of DP-b99 In China
Aug 10, 2010: D-Pharm Reports Positive Results From Phase III Cardiac Safety Study With DP-b99
Apr 15, 2010: D-Pharm Receives FDA Agreement Letter On Special Protocol Assessment For DP-b99 Study
Apr 15, 2010: D-Pharm Receives FDA Agreement Letter On Special Protocol Assessment For DP-b99 Study
Dec 31, 2009: D-Pharm Announces Enrollment Of First Patient In Phase III Efficacy Study Of DP-b99
Jun 08, 2009: D-Pharm Receives FDA Clearance To Commence A Phase III Trial Of DP-b99 In Acute Stroke Patients
Mar 04, 2008: D-Pharm Completes Pre-IND Meeting With The FDA For Treatment Of Acute Stroke With DP-b99
May 29, 2007: D-Pharm Announces Presentation Of Phase IIb Trial Results Of DP-b99 At The European Stroke Conference
Oct 23, 2006: D-Pharm Grants An Exclusive License For DP-b99 In South Korea To Yungjin Pharmaceutical Company Ltd.
Aug 01, 2006: D-Pharm Completes Enrollment For The Phase IIb Trial Of DP-b99
Financial Deals Landscape
D-Pharm Ltd., Deals Volume Summary, 2004 to YTD 2010
D-Pharm Ltd., Deals Summary By Region, 2004 to YTD 2010
D-Pharm Ltd., Deals Summary, 2004 to YTD 2010
D-Pharm Ltd. Detailed Deal Summary
Asset Purchase
D-Pharm Reacquires Rights To DP-VPA From Shire
Venture Financing
D-Pharm Secures $10 Million In Series A Financing
Equity Offering
D-Pharm Completes Rights Offering Of $14 Million
D-Pharm Completes Initial Public Offering Of $7.14 Million
Licensing Agreements
D-Pharm Enters Into Licensing And Co-Development Agreement With Wanbang Biopharma
D-Pharm Enters Into Licensing Agreement With Yungjin Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS